417 related articles for article (PubMed ID: 31023785)
1. Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.
Korfhage J; Lombard DB
Mol Cancer Res; 2019 Jul; 17(7):1417-1428. PubMed ID: 31023785
[TBL] [Abstract][Full Text] [Related]
2. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
[TBL] [Abstract][Full Text] [Related]
3. The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor.
Zhang X; Murray B; Mo G; Shern JF
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32182803
[TBL] [Abstract][Full Text] [Related]
4. Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome.
Imagawa E; Higashimoto K; Sakai Y; Numakura C; Okamoto N; Matsunaga S; Ryo A; Sato Y; Sanefuji M; Ihara K; Takada Y; Nishimura G; Saitsu H; Mizuguchi T; Miyatake S; Nakashima M; Miyake N; Soejima H; Matsumoto N
Hum Mutat; 2017 Jun; 38(6):637-648. PubMed ID: 28229514
[TBL] [Abstract][Full Text] [Related]
5. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state.
Kochat V; Raman AT; Landers SM; Tang M; Schulz J; Terranova C; Landry JP; Bhalla AD; Beird HC; Wu CC; Jiang Y; Mao X; Lazcano R; Gite S; Ingram DR; Yi M; Zhang J; Keung EZ; Scally CP; Roland CL; Hunt KK; Feig BW; Futreal PA; Hwu P; Wang WL; Lazar AJ; Slopis JM; Wilson-Robles H; Wiener DJ; McCutcheon IE; Wustefeld-Janssens B; Rai K; Torres KE
Acta Neuropathol; 2021 Sep; 142(3):565-590. PubMed ID: 34283254
[TBL] [Abstract][Full Text] [Related]
6. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.
Lee W; Teckie S; Wiesner T; Ran L; Prieto Granada CN; Lin M; Zhu S; Cao Z; Liang Y; Sboner A; Tap WD; Fletcher JA; Huberman KH; Qin LX; Viale A; Singer S; Zheng D; Berger MF; Chen Y; Antonescu CR; Chi P
Nat Genet; 2014 Nov; 46(11):1227-32. PubMed ID: 25240281
[TBL] [Abstract][Full Text] [Related]
7. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.
Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
[TBL] [Abstract][Full Text] [Related]
8. PRC2-complex related dysfunction in overgrowth syndromes: A review of EZH2, EED, and SUZ12 and their syndromic phenotypes.
Cyrus S; Burkardt D; Weaver DD; Gibson WT
Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):519-531. PubMed ID: 31724824
[TBL] [Abstract][Full Text] [Related]
9. A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.
Svrlanska A; Reichel A; Schilling EM; Scherer M; Stamminger T; Reuter N
J Virol; 2019 May; 93(9):. PubMed ID: 30814291
[TBL] [Abstract][Full Text] [Related]
10. H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumours.
Lyskjaer I; Lindsay D; Tirabosco R; Steele CD; Lombard P; Strobl AC; Rocha AM; Davies C; Ye H; Bekers E; Ingruber J; Lechner M; Amary F; Pillay N; Flanagan AM
J Pathol; 2020 Oct; 252(2):151-164. PubMed ID: 32666581
[TBL] [Abstract][Full Text] [Related]
11. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
12.
Oppel F; Ki DH; Zimmerman MW; Ross KN; Tao T; Shi H; He S; Aster JC; Look AT
Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32651197
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical evaluation of H3K27 trimethylation in malignant peripheral nerve sheath tumors.
Otsuka H; Kohashi K; Yoshimoto M; Ishihara S; Toda Y; Yamada Y; Yamamoto H; Nakashima Y; Oda Y
Pathol Res Pract; 2018 Mar; 214(3):417-425. PubMed ID: 29482987
[TBL] [Abstract][Full Text] [Related]
14. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
[TBL] [Abstract][Full Text] [Related]
15. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
[TBL] [Abstract][Full Text] [Related]
16. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
[TBL] [Abstract][Full Text] [Related]
17. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
[TBL] [Abstract][Full Text] [Related]
18. The noncanonical role of EZH2 in cancer.
Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
20. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.
Wu H; Zeng H; Dong A; Li F; He H; Senisterra G; Seitova A; Duan S; Brown PJ; Vedadi M; Arrowsmith CH; Schapira M
PLoS One; 2013; 8(12):e83737. PubMed ID: 24367611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]